Digital Genome Market Analysis And Forecast To 2032: By Product (Sequencing & Analyzer Instruments, DNA/RNA Analysis Kits, Sequencing Chips, Sequencing & Analysis Software, Sample Preparation Instruments), By Application (Microbiology {Biological, Clinica

The global Digital Genome Market was valued at USD 28.2 Billion in 2022 and it is anticipated to grow up to USD 64.6 Billion by 2032, at a CAGR of 8.6% during the forecast period.

Deep learning is a subset of machine learning in artificial intelligence (AI) that has networks capable of learning unsupervised from data that is unstructured or unlabeled. Also known as deep neural learning or deep neural networks (DNNs), deep learning models are neural networks (algorithms used to simulate the workings of the human brain in order to recognize patterns) that can learn and make predictions on their own by analyzing data, finding patterns, and making decisions.

Market Trends and Drivers

Surge in adoption of precision medicine will remain a key growth driver

The demand for digital genome is rapidly gaining popularity owing to continuous reduction in the cost and time required. The sequencing is widely used in the field of oncology, reproductive health and genetics. As a result, firms such as Illumina, Thermo Fisher and Qiagen are developing new innovative technologies in the field of genomics. Digital genomics market will further grow as rising application of sequencing in diagnosis of genetic disorders such as Duchenne Muscular Dystrophy, Fragile X syndrome and FAM Hypercholesterolemia etc. Advent of new technology coupled with rising demand of precision medicines will escalate market over forecast period. The major factors limiting the growth of digital genome market is lack of awareness regarding the digital genome, security & privacy of patient data, and incorrect results. In addition, lack of trained staff for digital genome in various developing economies will further impede the industry growth.

Market Restraints and Challenges

There are a few key restraints and challenges in Digital Genome market. Whole-genome sequencing can be less efficient at predicting some conditions than biochemical tests. This means that WGS would need to be combined with the existing screening process, rather than replacing it. Moreover, the test is limited in its ability to detect mosaicism. This technology is limited in its ability to accurately identify variants occurring in regions with high sequence identity to other regions of the genome.

The report analyses the global Digital Genome Market based on component, application, end-use, and region.
Global Digital Genome Market by Product
By product, the market is segmented into Sequencing & Analyzer Instruments, DNA/RNA Analysis Kits, Sequencing Chips, Sequencing & Analysis Software, and Sample Preparation Instruments. The market for DNA/RNA analysis kits are growing rapidly. With increasing investments and funding for research on life science, the adoption of digital genome is growing rapidly. Furthermore, high demand for various genotypic analysis and protein analysis are significantly contributing towards demand of digital genomics. The key players operating in the market have further developed advanced process of analysis of genes. With escalating research for genetics, stem cells and oncology, the need for DNA / RNA analysis kits will increase over estimated time frame. The key players of market, Thermo Fisher Scientific, GenomeMe, BiogeniQ and Nanostring has a wide array of kits for tumor gene analysis. The companies have developed kits where quantification of protein as well as analysis of gene expression can be performed in one experiment. The increasing demand for tumor gene analysis and advanced platforms will further propel demand for genome in near future.
Global Digital Genome Market by Application
By application, the Digital Genome Market is classified into Microbiology, Reproductive & Genetic, Transplantation, Livestock and Agriculture, Forensics, and Research and Development. Of these microbiogy held the largest market share of around xx% in 2022. A digital genome acts as a supporter that offers instant access to the trait sequences to resolve the custom queries. Advancement in genomics has greatly contributed to development of candidate gene approach and it is one of the most commonly used techniques to identify genes underlying disease traits. More recently, with genomic resources accessible through public Web, DigiCGA (Digital Candidate Gene Approach) have come as a new development in this field. DigiCGA, is an approach that is still in nascent stage but has already achieved some primary success in cancer gene discovery. The predictive analysis through digital genome has started being used widely. This will contribute to digital genome market growth.
Global Digital Genome Market by End-user
Based on end-use. It is segmented into Diagnostics & Forensic Labs, Academic Research Institutes, Hospitals, and Bio-Pharmaceutical Companies. Forensic labs are using next-generation sequencing technologies such as Illumina sequencing by synthesis (SBS) for high performance and error-free results. They also use PCR and capillary electrophoresis- based methods widely for DNA testing. National DNA database aids in investigation and identification of suspects, owing to this various country are trying to establish criminal intelligence databases that resulted in increased number of samples for DNA processing. Due to wide range of applications of digital genomics such as identification of missing persons, ancestry investigations, kinship testing and human identification demand for digital genomics is expected to increase by forensic labs.

Geographical Analysis of Global Digital Genome Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the market with a revenue share of over xx% in 2022, which is attributed to increased investments in artificial intelligence and neural networks. The genomic industry in U.S is still in its growing phase and is expected to grow at a fast pace in the coming years. The availability of new genome sequencing technologies, well-established healthcare infrastructure, increasing geriatric population are contributing towards revenue growth of market. Demand for precision medicines is rising in the country. Furthermore, in 2018 FDA has approved various drugs such as Lynparza & Blincyto that are tailored to specific characteristics of an individual. Genes are responsible for cause of many rare genetic disorders such as hutchinson-gilford progeria, psoriasis, cystic fibrosis, Rett's syndrome, etc. These diseases are affecting about 25 million people in united states. Researchers are using genomics to treat such genetic disorders by innovating new precision medicines and early diagnosis tools. Hospitals in the U.S. are also using genomics in detection and treatment of cancer. The biotechnology and pharmaceutical sectors in the U.S are marked by rapid growth that can further have positive impact of genomics market. The cost of sequencing genome is reducing and awareness among the people about importance of sequencing is rising, that will significantly propel growth of genomics in the country.

Major Players in the Global Digital Genome Market

The key players in the Digital Genome Market  Agilent Technologies, Inc., Becton Dickinson, Pacific Biosciences, Perkin Elmer, Sigma Aldrich and Thermo Fisher, among others.

COVID-19 Impact:

The COVID-19 pandemic is an unprecedented health concern and has significantly impacted the digital genome market worldwide. The pandemic has positively impacted the demand for digital genome software and products. For instance, as per a February 2022 published article titled, "Covid-19 and Artificial Intelligence: Genome sequencing, drug development, and vaccine discovery", the sequence of SARS- CoV-2 was identified with the help of AI and also aids in the prompt identification of variants of concern (VOC) as delta strains and Omicron. In addition, as per a May 2022 update by the Pan American Health Organization (PAHO), the COVID-19 Genomic Surveillance Regional Network was created in 2020 not only to strengthen the sequencing capacity in the participating laboratories but also for them to establish a routine SARS-CoV-2 genomic sequencing, as a strategy to increase the amount of genetic sequence data available to the global community, which is critical to support the development of diagnostic protocols, the information for vaccine development and to better understand the evolution and molecular epidemiology of the SARS-CoV-2. Moreover, with the introduction of vaccines and the upliftment of lockdown restrictions, the market is expected to increase the demand for digital genome products, thereby contributing to market growth.

Recent Developments:

• In May 2022, Gencove, one of the leading low-pass whole genome sequencing and analysis software companies, along with NEOGEN Corporation, launched the InfiniSEEK, a revolutionary, cost-effective solution for whole genome sequencing and targeted SNP analysis from two trusted leaders in genomics.
• In March 2022, LetsGetChecked, a leading healthcare solutions company, acquired Veritas Genetics Inc. and Veritas Intercontinental, pioneers in genomics that share a scalable platform enabling the rapid interpretation of genetic information from a single gene to the whole genome. The strategic move signifies a crucial advancement in LetsGetChecked’s mission to empower individuals to take control of their health and enable both consumers and healthcare partners to be more proactive in healthcare management.

Frequently Asked Questions

Q1. How big is the Deep Learning Market?Ans. The global Digital Genome Market was valued at USD 47.3 Billion in 2022 and it is anticipated to grow up to USD 379.4 Billion by 2032, at a CAGR of 23.1% during the forecast period.Q2. What is the Digital Genome Market growth rate?Ans. The growth rate of the Digital Genome Market is 23.1%Q3. Which region holds a major market share for the market?Ans. North America holds a major market share of the Digital Genome Market in 2022.Q4. Which segment accounted for the largest Digital Genome Market share?Ans. By end-use, the automotive segment accounted for the largest Digital Genome Market share.Q5. Who are the key players in the kidney stones management market?Ans. The global Digital Genome Market report includes players such Agilent Technologies, Inc, Becton Dickinson, Pacific Biosciences, Perkin Elmer, Sigma Aldrich, Thermo Fisher Scientific, Qiagen,  F. Hoffmann-La Roche Ltd., GE Healthcare, and GenMark Diagnostics, Inc.. among others.Q6. What are the factors driving the Digital Genome Market growth?Ans. The major factors driving the growth of the market are the rapid adoption of cloud-based technology across several industries is fueling the growth of the market.Q7. What are the key growth strategies of Digital Genome Market players?Ans. The key growth strategies of Digital Genome Market players are product launch and product approval.Q8. Which region will provide more business opportunities for the Digital Genome Market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for the Digital Genome Market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.